Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 61% of modeled bridge. Strengths: Bed Count, Commercial Payer %. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $0.4M (vs $0.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $225K | $225K | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $216K | $8K | $224K | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $34K | $102K | $137K | $431K | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $10K | $10K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 49.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $56K | $112K | $168K | $225K | $225K | $225K | $225K |
| Denial Rate Reduction | $0 | $56K | $112K | $168K | $224K | $224K | $224K | $224K |
| A/R Days Reduction | $0 | $46K | $91K | $137K | $137K | $137K | $137K | $137K |
| Clean Claim Rate | $0 | $5K | $10K | $10K | $10K | $10K | $10K | $10K |
| Cumulative | $0 | $163K | $325K | $483K | $595K | $595K | $595K | $595K |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $595K is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 43% / 5.9x | 47% / 7.0x | 51% / 8.0x | 53% / 8.5x | 55% / 9.0x |
| 9.0x | 37% / 4.9x | 42% / 5.8x | 46% / 6.7x | 48% / 7.2x | 50% / 7.6x |
| 10.0x | 33% / 4.1x | 37% / 4.9x | 42% / 5.7x | 44% / 6.1x | 46% / 6.5x |
| 11.0x | 28% / 3.4x | 33% / 4.2x | 37% / 4.9x | 39% / 5.3x | 41% / 5.7x |
| 12.0x | 23% / 2.9x | 29% / 3.5x | 33% / 4.2x | 36% / 4.6x | 37% / 4.9x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -19% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 7.7x, adding 0.7 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $6.2M | — | $6.2M | 55.3% |
| Year 1 | $6.4M | +$397K | $6.8M | 60.5% |
| Year 2 | $6.6M | +$595K | $7.2M | 64.0% |
| Year 3 | $6.8M | +$595K | $7.4M | 65.8% |
| Year 4 | $7.0M | +$595K | $7.6M | 67.6% |
| Year 5 | $7.2M | +$595K | $7.8M | 69.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $112K | $168K | $225K | $270K |
| Denial Rate Reductio | $112K | $168K | $224K | $269K |
| A/R Days Reduction | $68K | $102K | $137K | $164K |
| Clean Claim Rate | $5K | $7K | $10K | $12K |
| Total | $298K | $446K | $595K | $714K |
Peer Context — Where This Hospital Sits
Key metrics vs 26 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 55.3% | -26.5% | -14.7% | -7.8% | P96 |
| Net-to-Gross | 34.7% | 40.9% | 44.3% | 49.0% | P8 |
| Occupancy | 18.1% | 31.4% | 44.2% | 63.6% | P12 |
| Rev/Bed | $749K | $994K | $1.3M | $1.9M | P12 |
| Exp/Bed | $334K | $1.2M | $1.6M | $2.3M | P4 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.